Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Dr. Reddy's Laboratories Archives - The Pharma Times | Pharma & Health Care News Portal

Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories announces the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR)in the U.S. Market

Hyderabad, September 07, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred…

5 years ago

Dr. Reddy’s Laboratories announces the launch of Versavo® (bevacizumab biosimilar) in India

Hyderabad, August 22, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched…

5 years ago

Dr. Reddy’s Laboratories announces the launch of Pregabalin Capsules in the U.S. Market

Hyderabad, July 30, 2019:, Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred…

5 years ago

Dr. Reddy’s Q1 FY20 Financial Results

Hyderabad, July 29, 2019: Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated…

5 years ago

Dr. Reddy’s Laboratories announces the launch of Ramelteon Tablets, in the U.S. Market

Hyderabad, July 23, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together…

5 years ago

Dr. Reddy’s Laboratories announces first-to-market launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL)Single-dose Vial in the U.S. Market

Hyderabad, July 04, 2019: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred…

5 years ago

Dr. Reddy’s Laboratories announces entering into a definitive agreement to sell its neurology branded products to Upsher-Smith Laboratories, LLC

Hyderabad, June 14, 2019: Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announces that it has entered into…

5 years ago

Dr. Reddy’s Laboratories Limited through its wholly owned subsidiary, Dr. Reddy’s Laboratories SA, announces positive topline results from Phase 2b study of PPC-06 in patients with moderate to severe plaque psoriasis

Hyderabad,June 11, 2019: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to…

5 years ago